A Multicentre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Patient-Reported Outcome Measures
June 2026
in “
British Journal of Dermatology
”
Studysummary In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →